Arcturus Therapeutics Holdings Inc. (ARCT) stock
ARCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/303% below fair value
$8.36−0.08 (-0.95%)
Close on Nov 13, 2026Market cap $237.62MP/E –Yield –
Arcturus Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Arcturus Therapeutics's total debt was $15.00M at Mar 31, 2025. For fiscal 2022 it was $60.66M, down 3.9% from the year before. The highest annual figure on record is $63.11M in fiscal 2021.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $60.66M | -3.9% |
| FY2021 | Dec 31, 2021 | $63.11M | +318.1% |
| FY2020 | Dec 31, 2020 | $15.10M | +0.7% |
| FY2019 | Dec 31, 2019 | $15.00M | +51.3% |
| FY2018 | Dec 31, 2018 | $9.91M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2025 | Mar 31, 2025 | $15.00M | -76.1% |
| Q3 FY2023 | Sep 30, 2023 | $20.00M | -68.5% |
| Q4 FY2022 | Dec 31, 2022 | $60.66M | -3.9% |
| Q3 FY2022 | Sep 30, 2022 | $59.74M | -1.8% |
| Q2 FY2022 | Jun 30, 2022 | $62.78M | +2.4% |
| Q1 FY2022 | Mar 31, 2022 | $63.50M | +3.6% |
| Q4 FY2021 | Dec 31, 2021 | $63.11M | +318.1% |
| Q3 FY2021 | Sep 30, 2021 | $60.83M | +303.5% |
| Q2 FY2021 | Jun 30, 2021 | $61.31M | +307.1% |
| Q1 FY2021 | Mar 31, 2021 | $61.27M | +307.7% |
| Q4 FY2020 | Dec 31, 2020 | $15.10M | +0.7% |
| Q3 FY2020 | Sep 30, 2020 | $15.08M | +50.5% |
| Q2 FY2020 | Jun 30, 2020 | $15.06M | +50.9% |
| Q1 FY2020 | Mar 31, 2020 | $15.03M | +51.6% |
| Q4 FY2019 | Dec 31, 2019 | $15.00M | – |
| Q3 FY2019 | Sep 30, 2019 | $10.02M | – |
| Q2 FY2019 | Jun 30, 2019 | $9.98M | – |
| Q4 FY2018 | Dec 31, 2018 | $9.91M | – |
See a number that looks wrong?